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As the world is struggling to control the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), there is an
urgency to develop effective control measures. Essential information is encoded in the virus genome sequence with accu-
rate and complete SARS-CoV-2 sequences essential for tracking the movement and evolution of the virus and for guiding
efforts to develop vaccines and antiviral drugs. While there is unprecedented SARS-CoV-2 sequencing efforts globally, ap-
proximately 19 to 43 per cent of the genomes generated monthly are gapped, reducing their information content. The cur-
rent study documents the genome gap frequencies and their positions in the currently available data and provides an alter-
native primer set and a sequencing scheme to help improve the quality and coverage of the genomes.
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1. Introduction
Since the first report on 30 December 2019 in Wuhan China and
the WHO declaration of the pandemic on 12 March 2020, the
novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2) (Holmes and Zhang 2020) and the associated disease
Coronavirus Disease 2019 (COVID-19) (Li et al. 2020; Yang et al.
2020) have continued to spread throughout the world, causing
>46 million infections and >1,200,000 death globally (Gardner
et al. 2020). The virus genome sequences carry important infor-
mation, which can be used to interpret the virus transmission,
evolution patterns and origin tracing. Furthermore, accurate and
complete genomic sequences are essential for monitoring diag-
nostics and developing novel therapeutics and vaccines. We
have seen an unprecedented amount of virus sequencing with
over 130,000 complete or nearly complete genome sequences of
SARS-CoV-2 now available in the GISAID database by the end of
September 2020 (Shu and McCauley 2017). Most of the sequences
have been generated by next generation sequencing using tar-
geted amplicon methods. A scan through SARS-CoV-2 genomes
from GISAID with the filter ‘complete genome’ revealed a high
frequency of gaps occurring across the genome, influencing the
overall genomics quality and interpretation. Here, we describe an
alternate primer scheme for whole-genome sequencing to im-
prove the genome sequence quality and coverage.
2. Documenting the problem
We retrieved genomes deposited to GISAID in September 2020
(9 months into the pandemic), using the ‘complete genome’ fil-
ter and sorting the genomes by sequencing platforms informa-
tion included in the metadata. Figure 1 illustrated the positions
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across the 30 kb genome of every stretch of 200 Ns (N200; nearly
the size of an amplicon) in the first genomes deposited in
September 2020 using the Illumina platform (Panel A; N¼ 3,000)
versus MinION platform (Panel B; N¼ 3,000). Histograms of gap
frequencies across the genomes are shown for each platform.
The gaps are not randomly distributed but occur with higher
frequency in a subset of positions across the genome. Although
genomes generated by the two platforms (Illumina and MinION)
show similar problem regions (nt 8,000–11,000, and nt 19,000–
24,000 relative to the reference genome NC_045512), the pat-
terns are not completely identical. Given the use of several
primer amplification schemes, we suspect the gaps in coverage
may be due to unexpected primer interactions, complicated se-
quence regions (odd composition or secondary structure), issues
with primer trimming during quality control of read data, or
some combinations of these factors.
The phenomenon is unlikely to be due to an isolated set of
genomes as we observed similar N200 frequencies in genomes
submitted from each month of the pandemic (Table 1), suggest-
ing that gaps in coverage is a more general phenomenon. Of
note, genomes generated using Ion Torrent show much lower
levels of N200 (Table 1). The very low frequency of large gaps in
the Ion Torrent data may be due to the use of a dedicated alter-
native primer set (Alessandrini et al. 2020). There have been dis-
cussions and reports on the SARS-CoV-2 genome changes due
to sequencing errors as well as long gaps in the genomes due to
missing amplicons from the amplicon-approach sequencing
(De Maio et al. 2020; Page et al. 2020). Updates of the ARTIC pri-
mers have been presented in late March 2020 to address these
issues (Quick and Loman 2020; Tyson et al. 2020). Additional
reports of longer amplicon methods have been published (Eden
et al. 2020; Freed et al. 2020; Gonzalez-Reiche et al. 2020), includ-
ing methods to use a subset of ARTIC primers to generate longer
amplicons (Itokawa et al. 2020).
However, the percentage of reported complete genomes in
GISAID with 1 or more N200s continues, with 10,611 (28 per
cent) of the 38,228 genomes deposited in September 2020 having
1 or more N200 gaps (Table 1), indicating the challenges remain
largely unsolved.
3. Detailed analysis of gaps
A more focused analysis of the frequent gaps is provided in
Fig. 2. The gap pattern between nt 19,000 and 24,000 (relative to
the reference genome NC_045512) is shown for both MinION
and Illumina sequences (first 3,000 genomes of each deposited
in September 2020 with at least one 200 N motif). For reference,
the positions of the ARTIC primers (v.1) in the region are indi-
cated (middle panel). A histogram of gap start positions (top
panel) and the individual genome gaps (bottom panel) are also
shown.
The peaks of gap start positions frequently lie between for-
ward primerL from Amplicon n and reverse primerR from
Amplicon n1, for both MinION and Illumina data. Because of
overlapping amplicons commonly used, if a single amplicon is
missing from the sequencing library (amplicon 74 for example),
the resulting gap in coverage would not be the complete ampli-
con 74 but would span from the 30 end of the adjacent amplicon
73 (after primer and quality trimming) to the 50 end of adjacent
amplicon 75 (after primer and quality trimming). The calculated
gaps generated by such amplicon loss have a median length of
270.5 nt, which is close to the the observed median gap length
in the MinION data (258 nt) or Illumina data (262 nt) from
September 2020. This arrangement is outlined in the
Supplementary Fig. S1, Panel A.
4. Alternate primers as a potential solution to
avoid gapped genomes
We explored an alternate set of amplification primers (termed
the Entebbe primers) designed using methods we had previ-
ously used for MERS-CoV (Cotten et al. 2013), Norovirus (Cotten
et al. 2014), RSV (Agoti et al. 2015) and Yellow Fever virus (Phan
et al. 2019). Important for the design were the amplicon size and
the primer placement. For their implementation, the use of pri-
mers for the reverse transcription step, and the multiplexing of
the amplicons in two staggered sets were important for the PCR.
Our experience had suggested an optimum amplicon size of
around 1500 bp. The larger amplicons reduced the total primers
content of the reactions but still allowed high reverse transcrip-
tion efficiency (which, in our hands, declined beyond 1500 nt).
Here we describe primers designed for whole-genome sequenc-
ing of SARS-CoV-2, as well as sharing the detailed laboratory
methods that we used for reverse transcription, PCR
Figure 1. (updated graphics) Positions of 200 nt gaps across SARS-CoV-2
genomes listed as complete in GISAID. Genomes deposited in September 2020
(n¼38,228) were retrieved from GISAID, sorted by sequencing platform (MinION
versus Illumina) and genomes with at least one instance of 200 N were collected.
Panel A presents gaps in the first 3,000 MinION-generated genome sequences
deposited that contained at least on 200 N motif. Gaps>¼200 nt in each genome
are indicated with red bars. The upper panel histogram shows the frequency (in
30 nt bins) of gaps >¼200 nt motifs by start position on genomes. Panel B is the
same analysis of the first 3,000 Illumina-generated genome sequences in
September 2020 that contained at least one 200 N motif.
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amplification and MinION library preparation to successfully se-
quence the SARS-CoV-2 genome.
Briefly, the primer design (Fig. 3A) started with the set of
complete SARS-CoV-2 genome sequences available in the
GISAID database on 22 June 2020 (N¼ 21,687). Spaces and dis-
ruptive characters were removed from the sequence IDs and
the sequences were further screened to remove genomes con-
taining gaps of 6Ns or more, resulting in 17,220 clean genome
sequences. Next, all sequences were sliced into 33 nt strings
(33mers), with a 1 nt step and 606,389 unique 33mers were gen-
erated. The frequency of each 33mer was counted to identify
highly conserved 33mers. This counting method avoids the
multiple sequence alignment step commonly used in primer
design and becomes prohibitive with large and or diverse ge-
nome sets. This alignment-free approach allowed us to use all
suitable genome sequences of interest rather than a set that
could be conveniently aligned. Finally, primer-like 33mers
sequences were generated by trimming the sequences to a cal-
culated desired melting temperature and removing any primers
greater than 26 nt.
In the second step, we defined forward and reverse primer
target regions (bins) for the amplicons. For SARS-CoV-2, we se-
lected twenty amplicons with an overlap of 300 nt, regularly
spaced across the SARS-CoV-2 genome sequence (Fig. 3B). We
then selected the top conserved primer sequences (the highest
frequency primers) mapping in the 50 or 30 185 nt of each ampli-
con. For security, the two highest frequency primers per bin
were selected for the SARS-CoV-2 sequence, this provided some
insurance against primer failure either due to target evolution
or unexpected secondary structure. The binning and primer tar-
get locations for the final set of primers are shown in Fig. 2 and
the final calculated amplicon lengths were 1,495–2,093 nt.
The reverse transcription, PCR amplification and library pro-
tocols were modified to accommodate the new primers.
Important changes to note are the following. Reverse transcrip-
tion was performed using the reverse primers and reverse tran-
scription at 42C. The PCR cycling conditions (using Phusion

































1–31 January 2020 54 1 2 9 0 2 0 0 0 43 2
1–29 February 2020 126 2 2 44 0 9 0 5 0 65 4
1–31 March 2020 2,872 559 19 1,518 16 548 32 35 6 771 18
1–30 April 2020 12,411 3,745 30 4,970 38 1,286 27 264 0 5,424 26
1–31 May 2020 19,787 8,606 43 8,634 52 2,634 30 529 0 7,990 42
1–30 June 2020 21,665 8,723 40 7,043 36 3,844 35 629 2 10,149 47
1–31 July 2020 17,986 4,834 27 4,965 23 1,585 33 471 2 10,965 29
1–31 August 2020 17,276 4005 23 11,074 22 2,270 26 486 0 3,446 28
1–30 September 2020 38,227 10,611 28 22,740 23 7,973 44 580 1 6,934 28
aNumber of genomes with the annotation ‘complete’ retrieved from GISAID (https://www.gisaid.org/).
bGenomes were sorted by the presence or absence of the sequence N200.
c((The number of genomes with at least one N200)/total number of genomes)*100.
dNumber of genomes in GISAID for this period generated using any of the Illumina methods as noted in the GISAID ‘Sequencing technology metadata’.
e((The number of Illumina genomes with at least one N200)/total number of genomes)*100.
f,gNumber of genomes in GISAID for this period generated using any of the MinION methods as noted in the GISAID ‘Sequencing technology metadata’ and their
percentage.
h,iNumber of genomes in GISAID for this period generated using any of the Ion Torrent methods as noted in the GISAID ‘Sequencing technology metadata’ and their
percentage.
j,kNumber of genomes in GISAID for this period generated using unclear methods as noted in the GISAID ‘Sequencing technology metadata’ and their percentage.
Figure 2. Positions of 200 nt gaps across SARS-CoV-2 genomes stratified by
MinION or Illumina, in region nt 19,000 to 24,000. Genomes deposited in
September 2020 as ‘complete’ were retrieved from GISAID, sorted by sequencing
platform and by the presence of at least one N200 motif. For clarity, only the first
3,000 genomes in each set were plotted. Similar to Figure 1, gaps >¼200 nt in
each genome are indicated with red bars. The upper panel histogram shows the
frequency (in 30 nt bins) of gaps >¼200 nt motifs by start position on genome,
the middle panel plots the positions of ARTIC v.1 primers in the region
(pink¼ forward ‘left’ primers, red¼ reverse ‘right’ primers). Panel A: MinION-de-
rived genome sequences, Panel B: Illumina-derived genome sequences.






/ve/article/7/1/veab006/6128533 by guest on 06 O
ctober 2021
enzyme) were adjusted for the new Tms and an increased elon-
gation time required for the longer PCR products. Finally, the li-
brary purification steps were adjusted to recover longer PCR and
library products. A detailed step-by-step protocol is provided in
the Supplementary material.
5. Testing the performance of primers to
sequence SARS-CoV-2 using MinION
We tested the Entebbe primers performance for sequencing
SARS-CoV-2 from nucleic acid extracted from positive samples.
The amplicon sizes and genome coverage are summarised in
Fig. 4. In particular, panels A and B (Fig. 4) illustrate the ampli-
con products after the reverse transcription and PCR amplifica-
tion with the expected sizes of 1,400–2,000 bp. These amplicons
were then pooled and used for library preparation using the
MinION sequencing kits SQK-LSK109. Final libraries were quan-
tified and sequenced using a MinION Flow Cell (R9.4.1). The
resulting read data, after quality and primer and adapter trim-
ming, were then mapped to the SARS-CoV-2 Wuhan1 reference
genome NC_045512 (Fig. 4, panels C and D) to document se-
quence coverage across the genome. The twenty individual
amplicons are detected in the coverage pattern with small
peaks appearing where amplicons overlap. The coverage is con-
sistent across the genome with no missing amplicons and the
data were readily assembled into good coverage full genomes.
Initial experiments showed that amplicons 2 (spanning nt
2,400) and 16 (spanning nt 23,500) had reduced yields (Fig. 4,
panel C). The primer mixes were subsequently adjusted to in-
crease concentrations of amplicon 1 and 16 primers for reverse
transcription and PCR (see detailed protocol in Supplementary
materials), this improved yields relative to the other amplicons
(Fig. 4, panel D).
A set of SARS-CoV-2 clinical samples were tested with the
Entebbe primers/protocol. Respiratory swab samples from 111
PCR confirmed cases of SARS-CoV-2 infection were processed
for reverse transcription/PCR using the Entebbe primers and
protocol as described in Supplementary materials. If sufficient
amplicon DNA was generated after PCR, MinION libraries were
prepared, samples were sequenced on the MinION flowcells and
the resulting data were assembled into genomes. Figure 5A
shows the results of this validation test. Complete genomes
(fraction genome¼ 1) were obtained from samples up to Ct 35;
nineteen samples failed to yield sufficient amplicon DNA after
PCR stage (Fig. 5A, red markers) and five samples yielded
genomes with gaps > 842 nt. The PCR failures and the gapped
genomes were not strictly associated with higher Cts and their
distribution pattern is similar to the overall Ct distribution pat-
tern across the set of samples (Fig. 5, panel B) suggesting other
factors such as sample quality, extraction method, storage,
might be more critical than Ct in determining sequencing suc-
cess, at least in samples within the Ct range tested (up to Ct 37).
6. Conclusions
Given the urgency of controlling the SARS-CoV-2 pandemic and
the importance of having good quality SARS-CoV-2 genomes,
we are providing these alternative primers (the Entebbe pri-
mers) with detailed step-by-step laboratory protocols to the
community with the hope that they benefit from the new de-
sign. The costs and efforts of sequencing SARS-CoV-2 in the
large case numbers that are currently being seen are substantial
and if these new primers result in a higher proportion of gap-
less genomes, this will provide added value and will increase
the utility of the resulting data.
Supplementary data
Supplementary data are available at Virus Evolution online.
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